Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03423121
Other study ID # IRB00144766
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date June 19, 2018
Est. completion date July 5, 2022

Study information

Verified date April 2023
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to identify the safety and tolerability of bile acid supplementation in patients with progressive Multiple Sclerosis (MS). Participants will also be assessed for an impact of the bile acid on their immune system and gut microbiome. Half of the participants will receive the bile acid tauroursodeoxycholic acid (TUDCA) and half will receive placebo. The investigators believe participants who take TUDCA will have normalization of blood bile acid levels, a normalization of abnormal immune response and a normalization of the gut microbiome.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date July 5, 2022
Est. primary completion date April 28, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosis of Progressive MS based on Lublin Criteria - Low bile acid levels identified using targeted metabolomics analysis - On the same therapy for the past 6 months and not expected to switch therapy in the next 6 months - No relapse in the past 3 months Exclusion Criteria: - No previous history of liver disease or cholecystectomy - No stage IV/V chronic kidney disease or other severe metabolic derangements (e.g. poorly controlled thyroid disease or diabetes) - BMI < 15 kg/m2 and BMI > 40 kg/m2 - Female patients who are pregnant or nursing, or not willing to use contraception - Chronic antibiotic use - Corticosteroid treatment within the past 30 days - Known history of other neuroinflammatory, neurodegenerative or systemic autoimmune disease

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tauroursodeoxycholic Acid
Participants will be given 1 gram of Tauroursodeoxycholic acid twice daily in the form of four 250mg capsules.
Placebo oral capsule
Participants will be given four capsules of the placebo twice daily.

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland

Sponsors (1)

Lead Sponsor Collaborator
Johns Hopkins University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With at Least One Treatment-related Adverse Event Safety and tolerability will be assessed based on treatment-related adverse events in the two arms. 16 weeks
Primary Number of Total Treatment-related Adverse Events Safety and tolerability will be assessed based on treatment-related adverse events in the two arms. 16 weeks
Primary Incidence of Treatment-related Adverse Events (AE) Safety and tolerability will be assessed based on treatment-related adverse events in the two arms. AE incidence will be measured as total number of events per 1000 exposure years. 16 weeks
Secondary Change in Fasting Bile Acid Levels in Plasma The change of targeted bile acid levels over the course of 16 weeks (duration of the study) is reported.
Bile acid levels (ng/mL) were log transformed before analysis to approximate normal distribution. Units are log(levels) per 16 weeks. Values are derived from linear mixed-effects models.
Baseline to 16 weeks
Secondary Change in Microbiome Alpha-diversity Measured by Shannon Index at the End of the Study Change in Shannon index of the gut microbiota between baseline and end of study (16 weeks). Shot-gun metagenomic sequencing in first morning stool specimen was utilized to derive the microbiome composition. Higher values of the index indicate more diversity in the microbial community. The minimum value the Shannon index can take is 0 (no diversity). There is no upper limit to the index. Baseline to 16 weeks
Secondary Change in Flow Cytometric Assessments of Peripheral Blood Mononuclear Cells (PBMCs) Change in flow cytometric assessments over the course of 16 weeks (duration of the study).
Cells are expressed as ratios of their parent types. Units reported as change in the ratio per 16 weeks. Values are derived from linear mixed-effects models.
Baseline to 16 weeks
Secondary Change in Quality of Life Based on Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument Change in physical and mental health scores as assessed using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) instrument over the course of 16 weeks (duration of the study). This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. Two summary scores - physical health and mental health - are derived from a weighted combination of scale scores. Higher scores suggest a better quality of life. Scores can range from 0 to 100. Baseline to 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT02282826 - A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis Phase 1
Completed NCT02804594 - A Study of Oxidative Pathways in MS Fatigue Phase 2
Completed NCT04120675 - Efficacy of Early Harvest Olive Oil in Cognition of Primary (PPMS) or Secondary (SPMS) Progressive Multiple Sclerosis N/A
Completed NCT01719159 - Intrathecal Therapy With Monoclonal Antibodies in Progressive Multiple Sclerosis Phase 2
Enrolling by invitation NCT03552211 - Evaluation of the Incidence of Relapses in Patients With Biotin-treated Progressive Multiple Sclerosis
Recruiting NCT05740722 - Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis Phase 2
Completed NCT03980145 - G-EO Gait Rehabilitation Training in Progressive Multiple Sclerosis N/A
Completed NCT03269071 - Neural Stem Cell Transplantation in Multiple Sclerosis Patients Phase 1
Not yet recruiting NCT05811013 - Effects of Transcranial Static Magnetic Field Stimulation (tSMS) in Progressive Multiple Sclerosis N/A
Not yet recruiting NCT04289909 - Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS) N/A
Recruiting NCT05685784 - Multiple Sclerosis Prediction and Monitoring of Progression Study N/A
Completed NCT03493841 - Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple Sclerosis Phase 1
Completed NCT03302806 - Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
Recruiting NCT05441488 - Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis Phase 3
Recruiting NCT04695080 - ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis Phase 2/Phase 3
Recruiting NCT06451159 - A Study of KYV-101, a CD19 CAR T Cell Therapy, in Participants With Treatment Refractory Progressive Multiple Sclerosis Phase 1
Terminated NCT02580669 - Study by Magnetic Resonance Imaging in the Progressive Forms of Multiple Sclerosis N/A
Enrolling by invitation NCT05706220 - Visual Processing Speed and Objective Analysis of Ocular Movements in Multiple Sclerosis
Recruiting NCT01815632 - Assessment of Bone Marrow-derived Cellular Therapy in Progressive Multiple Sclerosis (ACTiMuS) Phase 2
Recruiting NCT01364246 - Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Phase 1/Phase 2